Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Zimmer Biomet Holdings, Inc. or Stryker Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Zimmer Biomet Holdings, Inc. and Stryker Corporation compare based on key financial metrics to determine which better meets your investment needs.
About Zimmer Biomet Holdings, Inc. and Stryker Corporation
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Latest Health Care Equipment & Supplies and Zimmer Biomet Holdings, Inc., Stryker Corporation Stock News
As of October 21, 2026, Zimmer Biomet Holdings, Inc. had a $18.1 billion market capitalization, compared to the Health Care Equipment & Supplies median of $412.0 million. Zimmer Biomet Holdings, Inc.’s stock is up 5.5% in 2026, up 3.4% in the previous five trading days and down 7.67% in the past year.
Currently, Zimmer Biomet Holdings, Inc.’s price-earnings ratio is 23.0. Zimmer Biomet Holdings, Inc.’s trailing 12-month revenue is $8.5 billion with a 9.5% net profit margin. Year-over-year quarterly sales growth most recently was 4.8%. Analysts expect adjusted earnings to reach $8.534 per share for the current fiscal year. Zimmer Biomet Holdings, Inc. currently has a 1.0% dividend yield.
As of October 21, 2026, Stryker Corporation had a $114.2 billion market cap, putting it in the 97th percentile of all stocks. Stryker Corporation’s stock is down 15.3% in 2026, up 5.7% in the previous five trading days and down 21.94% in the past year.
Currently, Stryker Corporation’s price-earnings ratio is 30.8. Stryker Corporation’s trailing 12-month revenue is $25.8 billion with a 14.4% net profit margin. Year-over-year quarterly sales growth most recently was 9.4%. Analysts expect adjusted earnings to reach $14.954 per share for the current fiscal year. Stryker Corporation currently has a 1.2% dividend yield.
How We Compare Zimmer Biomet Holdings, Inc. and Stryker Corporation Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Zimmer Biomet Holdings, Inc. and Stryker Corporation’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
Zimmer Biomet Holdings, Inc. and Stryker Corporation Stock Value Grades
| Company | Ticker | Value |
| Zimmer Biomet Holdings, Inc. | ZBH | C |
| Stryker Corporation | SYK | F |
Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.
Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.
AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.
Zimmer Biomet Holdings, Inc. has a Value Score of 54, which is Average.
Stryker Corporation has a Value Score of 18, which is Ultra Expensive.
The Value Stock Winner: No Clear Winner
Neither Zimmer Biomet Holdings, Inc. or Stryker Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Zimmer Biomet Holdings, Inc. or Stryker Corporation is the better investment when it comes to value.
Zimmer Biomet Holdings, Inc. and Stryker Corporation Growth Grades
| Company | Ticker | Growth |
| Zimmer Biomet Holdings, Inc. | ZBH | A |
| Stryker Corporation | SYK | A |
The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.
In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.
The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.
Zimmer Biomet Holdings, Inc. has a Growth Score of 100, which is Very Strong.
Stryker Corporation has a Growth Score of 89, which is Very Strong.
The Growth Grade Winner: It’s a Tie!
Looking at the Growth Grade breakdown above, both Zimmer Biomet Holdings, Inc. and Stryker Corporation have a grade of A. For investors who focus solely on a company’s upward growth, further research should be conducted into both companies’ other financial metrics before deciding whether to invest.
Zimmer Biomet Holdings, Inc. and Stryker Corporation’s Momentum Grades
| Company | Ticker | Momentum |
| Zimmer Biomet Holdings, Inc. | ZBH | C |
| Stryker Corporation | SYK | D |
Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.
Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.
Zimmer Biomet Holdings, Inc. has a Momentum Score of 46, which is Average.
Stryker Corporation has a Momentum Score of 30, which is Weak.
The Momentum Stock Winner: No Clear Winner
Neither Zimmer Biomet Holdings, Inc. or Stryker Corporation has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Zimmer Biomet Holdings, Inc. or Stryker Corporation is the better investment when it comes to momentum.
Don’t Forget Your Free Special Report on How A+ Grades Can Help You Make Investment Decisions
Other Zimmer Biomet Holdings, Inc. and Stryker Corporation Grades
In addition to Momentum, Growth and Value, A+ Investor also provides grades for Estimate Revisions and Quality.
Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).
AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.
These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Zimmer Biomet Holdings, Inc. and Stryker Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.
So, Which Is the Better Investment, Zimmer Biomet Holdings, Inc. or Stryker Corporation Stock?
Overall, Zimmer Biomet Holdings, Inc. stock has a Value Score of 54, Growth Score of 100 and Momentum Score of 46.
Stryker Corporation stock has a Value Score of 18, Growth Score of 89 and Momentum Score of 30.
Comparing Zimmer Biomet Holdings, Inc. and Stryker Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.
Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.
A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.
Included With AAII Platinum
at only 6.9%
Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.